RxDoctor Payments Data

Thomas Hargest, MD

Family Medicine · York, PANPI 1528082930

Payments from drug & device makers

$12,880in general payments, 2019–2025

Across 816 payments — averaging $15.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Pfizer$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • GSK$1K
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$12,865100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,880 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$165,720
Medicare patients
287
Services billed
3,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban116$134,812
OzempicSemaglutide62$88,095
JardianceEmpagliflozin56$75,516
RybelsusSemaglutide41$46,342
MounjaroTirzepatide32$45,619
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$44,811
JanuviaSitagliptin Phosphate27$35,854
FarxigaDapagliflozin Propanediol21$33,119
GlyxambiEmpagliflozin/Linagliptin17$27,823
ArexvyRsvpref3 Antigen/As01e/Pf91$27,781
ProliaDenosumab16$27,670
ShingrixVaricella-Zoster Ge/As01b/Pf92$19,998
MyrbetriqMirabegron26$17,810
XareltoRivaroxaban15$13,865
Breo ElliptaFluticasone/Vilanterol33$13,528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,212$134,812116 claims
Novo NordiskOzempic, Rybelsus$2,043$134,438103 claims
GSKTrelegy Ellipta, Arexvy, Shingrix, Breo Ellipta, Anoro Ellipta$1,030$117,501274 claims
Boehringer IngelheimJardiance, Glyxambi, Stiolto Respimat$742$110,65689 claims
Lilly USA, LLCMounjaro$1,160$45,61932 claims
MerckJanuvia$397$35,85427 claims
AstraZenecaFarxiga$1,192$33,11921 claims
AmgenProlia$208$27,67016 claims
Johnson & JohnsonXarelto$33$13,86515 claims
Sanofi-aventis U.S. LLCLantus$144$4,39721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in York

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →